Global Stem Cell Umbilical Cord Blood (UCB) Market 2015-2019

Global Stem Cell Umbilical Cord Blood (UCB) Market 2015-2019

Category : Diagnostic and Biotech
Published On : August  2015
Pages : 82

request-discount


TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

About Stem Cell UCB
UCB is the blood that remains in the placenta and the attached umbilical cord after childbirth. UCB contains stem cells that are unique, smart, and are capable of treating several life-threatening diseases. They are used in the treatment of hematopoietic and genetic disorders. The placental blood can produce 10 times more quantity of stem cells compared to the umbilical cord, which can in turn be used for the treatment of an adult patient. The cord blood that is collected during the childbirth is stored and cryopreserved. The storage of the cord blood can be done at private cord blood banks or public cord blood banks. This preserved blood can be used for the transplantation, and treatment of diseases at the later stages of life.

Technavio's analysts forecast the global stem cell UCB market to grow at a CAGR of 30.36% over the period 2014-2019.

Covered in this Report
The report covers the present scenario and the growth prospects of the global stem cell UCB market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the banking and utilization of UCB stem cells for the treatment of various disorders, such as cancers, blood disorders, metabolic disorders, immune diseases, and others.

Technavio's report, Global Stem Cell UCB Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global stem cell UCB market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA

Key Vendors
• Caladrius Biosciences 
• Celgene 
• Mesoblast 
• Pluristem Therapeutics

Other Prominent Vendors
• Athersys
• CHA Bio & Diostech 
• Cytori Therapeutics
• Nuo Therapeutics 
• Ocata Therapeutics 
• Opexa Therapeutics 
• Osiris Therapeutics 
• Teva Pharmaceuticals 
• United Therapeutics 

Key Market Driver
• Effective Treatment of Life-threatening Diseases
• For a full, detailed list, view our report

Key Market Challenge
• Stringent Regulations
• For a full, detailed list, view our report

Key Market Trend
• Growing Public Awareness
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

01. Executive Summary



02. List of Abbreviations



03. Scope of the Report



03.1 Market Overview



04. Market Research Methodology



04.1 Market Research Process



04.2 Research Methodology



05. Introduction



06. Process of Collection, Processing and Storage of Cord Blood Cells



06.1 Donor Evaluation



06.2 Collection Methods



06.3 Processing and Storage Methods



06.4 Sample Retention and Length of Storage



07. Facts: Cord Blood Units



08. US FDA Approved Stem Cell UCB Product



08.1 Hemacord



08.1.1 Mechanism of Action



08.1.2 Side Effects



09. Pipeline Analysis



09.1 Information on the Pipeline Candidates



09.1.1 PDA-002



09.1.2 PDA-001



09.1.3 PLX-PAD



09.1.4 PLX-R18



10. Market Landscape



10.1 Market Overview



10.2 Market Size and Forecast



10.3 Five Forces Analysis



11. Market Segmentation by Application



11.1 Cancers



11.2 Blood Disorders



11.3 Metabolic Disorders



11.4 Immune Disorders



11.5 Others



12. Market Segmentation by Storage



12.1 Public Cord Blood Bank



12.2 Private Cord Blood Bank



12.3 Public-Private Cord Blood Banks



13. Harmonization of Biobanking



14. Market Segmentation by End-users



14.1 Research Institutes



14.2 Pharmaceutical Companies



14.3 Biobanks



14.4 Hospitals



15. Geographical Segmentation



15.1 Stem Cell UCB Market in Americas



15.1.1 Market Size and Forecast



15.2 Stem Cell UCB Market in EMEA



15.2.1 Market Size and Forecast



15.3 Stem Cell UCB Market in APAC



15.3.1 Market Size and Forecast



16. Buying Criteria



17. Market Growth Drivers



18. Drivers and their Impact



19. Market Challenges



20. Impact of Drivers and Challenges



21. Market Trends



22. Trends and their Impact



23. Vendor Landscape



23.1 Competitive Scenario



23.1.1 Key News



23.1.2 Mergers and Acquisitions



23.2 Market Share Analysis 2014



23.2.1 Caladrius Biosciences



23.2.2 Celgene



23.2.3 Mesoblast



23.2.4 Pluristem Therapeutics



23.3 Other and Future Prominent Vendors



24. Global Stem Cell UCB Market: Key Takeaways



25. Key Vendor Analysis



25.1 Caladrious



25.1.1 Key Facts



25.1.2 Business Overview



25.1.3 Business Segmentation by Revenue 2014



25.1.4 Business Segmentation by Revenue 2013 and 2014



25.1.5 Geographical Segmentation by Revenue 2014



25.1.6 Business Strategy



25.1.7 Recent Developments



25.1.8 SWOT Analysis



25.2 Celgene



25.2.1 Key Facts



25.2.2 Business Overview



25.2.3 Business Strategy



25.2.4 Business Segmentation by Revenue



25.2.5 Sales by Geography



25.2.6 Key Information



25.2.7 SWOT Analysis



25.3 Mesoblast



25.3.1 Key Facts



25.3.2 Business Overview



25.3.3 Therapeutic Areas



25.3.4 Geographical Segmentation



25.3.5 Business Strategy



25.3.6 Recent Developments



25.3.7 SWOT Analysis



25.4 Pluristem



25.4.1 Key Facts



25.4.2 Business Overview



25.4.3 Geographical Presence



25.4.4 Business Strategy



25.4.5 Recent Developments



25.4.6 SWOT Analysis



26. Other Reports in this Series





List of Exhibits:

Exhibit 1: Market Research Methodology

Exhibit 2: Donor Evaluation Before Collection of Cord Blood Cells

Exhibit 3: Collection of Cord Blood Cells

Exhibit 4: Processing and Storage Methods of Cord Blood Cells

Exhibit 5: Stem Cell Transplantations by Patients Race in US

Exhibit 6: Pipeline Portfolio of Stem Cell UCB Products for Different Diseases

Exhibit 7: Global Stem Cell UCB Market 2014-2019 ($ millions)

Exhibit 8: Global Stem Cell UCB Market Segment by Application

Exhibit 9: Global Stem Cell UCB Market Segment by Storage

Exhibit 10: Organizations and Initiatives Toward Biobank Harmonization

Exhibit 11: Key Factors Involved in Harmonization of Biobanks

Exhibit 12: Key Focus Areas in Harmonization of Biobanks

Exhibit 13: Organizations and Initiatives in Harmonizing Science and Infrastructure

Exhibit 14: Initiatives on Biobanking Resource Tools and Databases

Exhibit 15: Global Stem Cell UCB Market Segment by End-users

Exhibit 16: Segmentation of Global Stem Cell UCB Market by Geography 2014

Exhibit 17: Stem Cell UCB Market in Americas 2014-2019 ($ millions)

Exhibit 18: Stem Cell UCB Market in APAC 2014-2019 ($ millions)

Exhibit 19: Stem Cell UCB Market in APAC 2014-2019 ($ millions)

Exhibit 20: Statistics of Stem Cell UCB Market : By Geography

Exhibit 21: Global Stem Cell UCB Market: Key Takeaways

Exhibit 22: Caladrious: Business Segmentation by Revenue 2014

Exhibit 23: Caladrious: Business Segmentation by Revenue 2013 and 2014 ($ millions)

Exhibit 24: Caladrious: Geographical Segmentation by Revenue 2014

Exhibit 25: Celgene: Business Segmentation by Revenue 2011-2013 ($ millions)

Exhibit 26: Celgene: Sales by Geography 2013

Exhibit 27: Mesoblast: Therapeutic Areas

Exhibit 28: Mesoblast: Geographical Segmentation

Exhibit 29: PLuristem: Geographical Presence



Enquiry Before Buy